| BIOXCEL THERAPEUTICS |
| USA |
| Gesundheit |
| US09075P2048 / A40YSR |
| BX20 (Frankfurt) / BTAI (NASDAQ) |
| FRA:BX20, ETR:BX20, BX20:GR, NASDAQ:BTAI |
| - |
| https://www.bioxceltherap.. |
|
BioXcel Therapeutics, Inc. is a biopharmaceutical company that leverages artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology. Its lead product, IGALMI, is a sublingual film approved for the acute treatment of a..
>Volltext.. |
| 28.33 Mio. EUR |
| 104.82 Mio. EUR |
| 0.56 Mio. EUR |
| -42.72 Mio. EUR |
| -60.43 Mio. EUR |
| -6.18 EUR |
| 103.24 Mio. EUR |
| 24.86 Mio. EUR |
| -49.82 Mio. EUR |
| 0.53 |
| -75.03% |
| -3.37% |
| - |
| - |
| - |
| - |
| BIOXCEL |
| 01.04.26 |
|
||||
|
||||
|
||||
|
||||
|